Download Mobile App

Video Library

Partner Sites

MedImaging

Novel Ultrasound-Launched Targeted Nanoparticle Eliminates Biofilm and Bacterial Infection

Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality

AI-Guided Ultrasound System Enables Rapid Assessments of DVT

New AI Method Captures Uncertainty in Medical Images

AI Assistance Improves Breast-Cancer Screening by Reducing False Positives

Rapid Diagnostic Platform Delivers Up To 30 Results from Single Drop of Body Fluid within 15 Minutes

By HospiMedica International staff writers
Posted on 18 Jan 2023

ALiA platform delivers multiple results with minimal drop of sample in 15 minutes at POC (Photo courtesy of ALiA BioTech) Crop Article Image

Thanks to the COVID-19 pandemic, the point-of-care testing (POCT) market is expected to double in size as compared to the pre-pandemic levels. Multiplexing remains the key technology differentiator in this growing field. By increasing the number of simultaneous assays, it becomes possible to identify the right biomarker, and consequently lower the cost and time needed to control a potential outbreak. Now, a next-generation rapid diagnostic platform that is capable of conducting multiplex testing in a single biochip within 15 minutes could become a game changer in the POCT market.

ALiA BioTech’s (Hong Kong) Lab-on-Chip platform is a patented POCT that is capable of delivering up to 30 results from a single drop of body fluid, including blood, serum, swab, or urine. ALiA has completed the R&D of its proprietary microfluidic and microarray technologies, and now aims to scale up the manufacturing of multiplex products for different disease panels. ALiA analyzer and its biochip panels for respiratory infection and tropical fever have been granted the CE marking, with the accredited ISO 13485 medical device quality management system. The company is in the process of securing regulatory approval in other regions, including the U.S., mainland China and Southeast Asia, and will enter into global strategic partnerships for developing biochips for various disease panels.

“A single test on our platform gives the fast track and accurate answer,” said Kelvin Chiu, CEO of ALiA BioTech. “Over the next five to 10 years, we shall develop more multiplex diseases panels and complete clinical trials and regulatory approval processes so that we can introduce more real-time rapid diagnostic panels that are critical to rescuing lives.”